-
Cost-Effectiveness of LGI-Flag in Austria: A Model-Based Evaluation
Sep 9, 2025, 16:22 PM -
Understanding Reimbursement and Access Policies for Immunoglobulins and Other Plasma-Derived Medicinal Products Across Europe
Sep 9, 2025, 16:22 PM -
The Greek Drug Price Negotiation Committee and Its Contribution in Optimizing the Management of EOPYY's Pharmaceutical Budget
Sep 9, 2025, 16:22 PM -
The Clinical and Economic Impact of the Introduction of Emicizumab as Prophylactic Treatment for Hemophilia A Patients in Greece
Sep 9, 2025, 16:22 PM -
Effectiveness and Safety of Radiofrequency Nucleolysis for Chronic or Acute Low Back Pain
Sep 9, 2025, 16:22 PM -
Increased Trends of Self-Optimized Submissions to NICE
Sep 9, 2025, 16:22 PM -
Challenges at the Interface Between EUHTA (JCA) and National HTA in Germany (AMNOG): Expected Limitations to Synergy Effects and Implications for AMNOG Dossier Preparation
Sep 9, 2025, 16:22 PM -
Assessing Public Health and Economic Benefits of Nirsevimab or RSVpreF for Preventing RSV-Related Outcomes in Japanese Infants
Sep 9, 2025, 16:22 PM -
A Budget Impact Analysis of Switching From Von Willebrand Factor/Factor VIII Plasma-Derived Concentrate With 2.4-1 Ratio to the Concentrate With 1-1 Ratio for the Management of Von Willebrand Disease in Qatar
Sep 9, 2025, 16:22 PM -
Impact of Maternal Vaccination Strategy on RSV-Related Hospital Burden Among Infants Aged Less Than One Year in France: A Cost-Effectiveness Analysis
Sep 9, 2025, 16:22 PM -
Robotic Surgery: A Budget Analysis in the Italian Healthcare Setting
Sep 9, 2025, 16:22 PM -
Epidemiological Analysis of Colorectal Cancer in Cyprus Amidst the Absence of Organized Screening Programs Data From 2000 to 2020
Sep 9, 2025, 16:22 PM -
Real-World Evidence in Action: Assessing Drug-Drug Interactions to Drive Value-Based Decisions
Sep 9, 2025, 16:22 PM -
Role of Technical Engagement in NICE Process Under Proportionate Approach to Technology Appraisals
Sep 9, 2025, 16:22 PM -
Patient-Reported Outcomes After Total Knee Arthroplasty: Comparisons Across TKA Procedures and PRO Domains
Sep 9, 2025, 16:22 PM -
MCDA Tool Adoption in Egypt: Room for Sustainability and Accessibility
Sep 9, 2025, 16:22 PM -
Assessing the Socioeconomic Value of Ocrelizumab Subcutaneous for Treating Relapsing Multiple Sclerosis in the Evolving Treatment Landscape in the United Kingdom
Sep 9, 2025, 16:22 PM -
Demonstrating the Importance of Modeling Rapid Cancer Progression in Screening Evaluations
Sep 9, 2025, 16:22 PM -
Evaluate the Statistical Utility After Transformation of a CDISC SDTM Database Into OMOP CDM
Sep 9, 2025, 16:22 PM -
Real-World Assessment Process to Identify Fit-for-Purpose Data Sources to Meet Milestones for Post-Marketing Requirements (PMR), Post Authorization Safety Studies (PASS), and Health Technology Assessment (HTA) Submissions Utilizing Source Exploration...
Sep 9, 2025, 16:22 PM
